PDS Biotechnology Corp (NAS:PDSB)
$ 1.64 -0.03 (-1.8%) Market Cap: 61.35 Mil Enterprise Value: 36.27 Mil PE Ratio: 0 PB Ratio: 2.74 GF Score: 31/100

PDS Biotechnology Corp at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 06:45PM GMT
Release Date Price: $5.22 (+2.15%)
Wayne Wu
Cantor Fitzgerald - Analyst

So good afternoon. My name is Wayne Wu and I am the associate on Louise Chen's Large Cap Pharma, BioPharma & Biotech team here at Cantor. Thank you so much for joining us today with our panel presentation with PDS Biotechnology as well as Immutep. We're thrilled to have Frank as well as Marc to give us their wonderful presentations. So let's start with Frank. Thank you.

Frank Bedu;Addo
PDS Biotechnology Corporation - CEO

Thank you very much for the introduction. Let's see. How do I move this forward? Okay. Okay. So I'm just before I start, I'd just like please to advise everyone to get comfortable and be familiar with the risk factors associated with PDS and as filed with the SEC.

So who is PDS Biotechnology? We are a mid to late clinical stage biotech company developing immunotherapies that train and activate the immune system to specifically target cancer. We are developing targeted immunotherapies based on the company's proprietary, Versamune T-cell activating technology platform.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot